Idera Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference
01 Noviembre 2006 - 7:15AM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced that Robert
Karr, M.D., President of Idera, will discuss the Company�s
Toll-Like Receptor - targeted drug discovery and development
programs and provide a general corporate overview at the Rodman
& Renshaw 8th Annual Healthcare Conference to be held at the
Palace Hotel in New York City. The presentation will begin at 9:55
a.m. (ET) on Monday, November 6, 2006. The presentation will be
available via live audio webcast on the Company�s website at
www.iderapharma.com and can be found under
http://iderapharma.com/webcasts.php. Archived replays will also be
located on the Company�s site following the event. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company with a pipeline of drug candidates to treat
cancer and infectious, respiratory, and autoimmune diseases.
Idera�s proprietary drug candidates are designed to modulate
Toll-Like Receptors (TLRs), the body�s first line of immune
defense. Idera�s pioneering DNA chemistry expertise enables it to
identify drug candidates for internal development and creates
opportunities for multiple collaborative alliances. Idera�s most
advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonist candidates for treating asthma and allergy.
For more information, visit www.iderapharma.com. Forward Looking
Statements This press release contains forward-looking statements
concerning Idera Pharmaceuticals, Inc. that involve a number of
risks and uncertainties. For this purpose, any statements contained
herein that are not statements of historical fact may be deemed to
be forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera�s
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera�s technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company�s
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company�s technology and prevent others from
infringing it; whether Idera�s cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera�s Quarterly Report on Form 10-Q filed on August 14, 2006,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements. Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced
that Robert Karr, M.D., President of Idera, will discuss the
Company's Toll-Like Receptor - targeted drug discovery and
development programs and provide a general corporate overview at
the Rodman & Renshaw 8th Annual Healthcare Conference to be
held at the Palace Hotel in New York City. The presentation will
begin at 9:55 a.m. (ET) on Monday, November 6, 2006. The
presentation will be available via live audio webcast on the
Company's website at www.iderapharma.com and can be found under
http://iderapharma.com/webcasts.php. Archived replays will also be
located on the Company's site following the event. About Idera
Pharmaceuticals, Inc. Idera Pharmaceuticals is a drug discovery and
development company with a pipeline of drug candidates to treat
cancer and infectious, respiratory, and autoimmune diseases.
Idera's proprietary drug candidates are designed to modulate
Toll-Like Receptors (TLRs), the body's first line of immune
defense. Idera's pioneering DNA chemistry expertise enables it to
identify drug candidates for internal development and creates
opportunities for multiple collaborative alliances. Idera's most
advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is
currently in a Phase 2 trial in oncology and in a Phase 1/2
chemotherapy combination trial in oncology. Idera has selected a
second TLR9 agonist, IMO-2125, as a lead candidate for treating
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonist candidates for treating asthma and allergy.
For more information, visit www.iderapharma.com. Forward Looking
Statements This press release contains forward-looking statements
concerning Idera Pharmaceuticals, Inc. that involve a number of
risks and uncertainties. For this purpose, any statements contained
herein that are not statements of historical fact may be deemed to
be forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera's technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether the Company will complete enrollment
of clinical trials in the time expected; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the results of preclinical studies will be
indicative of results that may be obtained in clinical trials;
whether the patents and patent applications owned or licensed by
Idera will protect the Company's technology and prevent others from
infringing it; whether Idera's cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera's Quarterly Report on Form 10-Q filed on August 14, 2006,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Idera Pharmaceutical (AMEX:IDP)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024